Press Releases

• • All Categories
  • C. difficile
  • Chikungunya
  • COVID-19
  • DUKORAL®
  • IXIARO®
  • Lyme Disease
  • Uncategorized

Filter By Year 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

March 31, 2009

2008: positive net income ¹ : Operating income: €8.9 million (+180%) Net income¹: €0.5 million 2009 targets: continuation of sustained growth Net cash at year-end 2009 > €20 million Financial visibility over the next 4 years

March 3, 2009

VIVALIS AND FORT DODGE ANIMAL HEALTH SIGN A COMMERCIAL LICENSE AGREEMENT TO USE THE EB66®CELL LINE FOR VIRAL VACCINES PRODUCTION.

February 17, 2009

VIVALIS AND BOEHRINGER INGELHEIM ANIMAL HEALTH SIGN A RESEARCH LICENSE AGREEMENT, WITH AN OPTION TO ENTER INTO A COMMERCIAL LICENSE AGREEMENT TO USE EB66® PLATFORM FOR VETERINARY VACCINES PRODUCTION

February 9, 2009

VIVALIS ACHIEVES SIGNIFICANT MILESTONES IN THE DEVELOPMENT OF HUMAN FLU VACCINES BASED ON THE EB66® CELL LINE

February 3, 2009

NOVAVAX AND VIVALIS SIGN A RESEARCH LICENSE AGREEMENT TO USE THE EB66® CELL LINE FOR THE PRODUCTION OF VIRUS LIKE PARTICULE BASED VACCINES. Rockville

January 27, 2009

2008 revenue multiplied by 5 to €5.4 million Net cash at December 31, 2008: €22.7 million, up €1.3 from the first half 4 years of financial visibility

January 21, 2009

VIVALIS AND INNATE PHARMA SIGN A COLLABORATION AND COMMERCIAL LICENSE AGREEMENT TO DEVELOP INNATE’S NOVEL MONOCLONAL ANTIBODY, TO BE MANUFACTURED WITH VIVALIS’ EB66® PLATFORM, FOR RARE CUTANEOUS CANCERS

January 13, 2009

PURSUIT OF ROBUST COMMERCIAL EXPANSION IN 2009 TARGET: 6 TO 7 NEW LICENSES INCLUDING TWO COMMERCIAL LICENSES

December 17, 2008

VIVALIS AND KAKETSUKEN SIGN TWO COMMERCIAL LICENSE AGREEMENTS TO USE THE EBx® PLATFORM FOR THE PRODUCTION OF HUMAN AND VETERINARY VIRAL VACCINES.

December 10, 2008

VIVALIS SECURES IMPORTANT PATENTS COVERING THE USE OF EB66® PLATFORM TO PRODUCE RECOMBINANT VACCINES